{"entity":{"id":"ubix-therapeutics","kind":"company","name":"Ubix Therapeutics","aka":["Ubix Therapeutics, Inc.","유빅스테라퓨틱스"],"tldr":"Ubix Therapeutics is a Korean company making medicines that make cancer cells break down a target protein rather than just block it. Its lead drug destroys BTK, a protein that drives B-cell blood cancers, including forms resistant to current BTK inhibitors.","summary":"Ubix Therapeutics, Inc., based in Songpa-gu, Seoul, develops targeted protein degraders it calls Degraducers. Its lead programme UBX-303-1 (registered as UBX-303061) degrades Bruton's tyrosine kinase (BTK) and, according to the company, showed antitumour activity in preclinical models with wild-type BTK and the C481S resistance mutation; UBX-106 and UBX-306 are undisclosed immuno-oncology programmes. In March 2026 the company withdrew its application for preliminary review of a KOSDAQ listing, saying it would reapply after clinical results and licensing progress. Its first registered cancer trial, NCT06590961, a phase 1a/1b dose-escalation and expansion study of UBX-303061 in relapsed or refractory B-cell malignancies at sites in the United States, Poland and Korea, was posted on ClinicalTrials.gov in September 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://ubixtrx.com/"},{"label":"Pipeline","url":"https://ubixtrx.com/pipeline"},{"label":"ClinicalTrials.gov: phase 1 trial of UBX-303061 (NCT06590961)","url":"https://clinicaltrials.gov/study/NCT06590961"}],"tags":[],"related":[],"cancers":["cll","non-hodgkin-lymphoma"],"sections":["targeted-therapy"],"technologies":["protac-degrader"],"targets":["btk"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and financing not stated on the pages read. The listing withdrawal is from a Korean-language headline on the company home page. The pipeline page names chronic lymphocytic leukaemia among intended indications; text was partly in Korean. Read on 29 October 2026."],"hq":"Seoul","country":"KR","companyType":"biotech","website":"https://ubixtrx.com/","stage":"growth","investors":[],"funding":[]},"route":"/companies/ubix-therapeutics/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"target":[{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/"}]}}